|  |
| --- |
| http://www.hms-cme.net/732059-1801/images/header2017.jpg |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| [**ACCREDITATION**](http://www.hms-cme.net/732059-1801/#accreditation) | [**REGISTRATION**](https://cmeregistration.hms.harvard.edu/d/m5qm06/4W) | [**SCHEDULE**](http://www.hms-cme.net/732059-1801/#schedule) | [**FACULTY**](http://www.hms-cme.net/732059-1801/#faculty) | [**BROCHURE**](http://www.hms-cme.net/732059-1801/images/732059-1801_web.pdf) |

|  |
| --- |
|  |

**Course Description**Care for patients with solid tumors, hematologic malignancies, and benign hematologic disorders continues to evolve with the development of novel therapeutic agents and testing modalities, accumulation of clinical trial data, and ongoing revisions to expert guidelines. Oncologists, hematologists, and other clinicians who participate in the care of patients with these disorders are challenged to stay current on the latest diagnosis, treatment, and management advances. This intensive six-day course provides a comprehensive review of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions. Primary emphasis will be placed upon the broad area of medical management within a multidisciplinary environment. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed. Teaching will be primarily through lectures, panels, and case discussions with the assistance of appropriate visual aids.**Cancer Medicine and Hematology 2017** is an intensive, 6-day educational activity that is specifically designed to provide clinicians with a comprehensive review of up-to-date practice standards for a broad range of solid tumors, hematologic malignancies, and benign hematologic disorders. Taught by expert Harvard Medical School faculty as well as invited experts, the course features discussion of the most recent clinical trial data, recently updated guidelines, and current expert opinion with impacts on management decisions for patients with these disorders. The highly interactive course is presented through a mixture of engaging lectures followed by question and answer sessions, case-based presentations and panel reviews of participants’ challenging cases, and disease-specific panel discussions. A two-volume syllabus and a thumb drive with copies of each speaker’s outline and slides ensures that clinicians can return to this material again and again as needed to inform and improve their practices, leading to improved patient outcomes.**Course Objectives**Upon completion of this course, participants will be able to:* Incorporate new and emerging clinical data into expert recommended best practices for diagnosing, evaluating, and treating patients with breast cancer
* Develop personalized treatment strategies for patients with lung, head and neck cancers, based on appropriate molecular testing and incorporating newly approved systemic therapies when appropriate
* Choose from available systemic agents as part of multimodal treatment approaches for patients with gastrointestinal and neuroendocrine cancers based on current molecular testing and risk assessment methods
* Develop treatment plans for prostate, testicular, renal, and bladder cancers that are tailored to individual patients’ risk factors and characteristics
* Create evidence-based care plans for patients with ovarian, cervical, endometrial, and trophoblastic cancers that incorporate recent advances in diagnosis and management
* Update treatment practices in a wide range of less common cancers, including brain tumors, thyroid cancer, melanoma, sarcoma, and mesothelioma, based on emerging clinical evidence and current expert recommendations
* Develop evidence-based management plans for patients with benign hematologic disorders, incorporating new diagnostic strategies and novel therapies into current treatment paradigms
* Create optimized supportive care and survivorship plans for patients with cancer that take into account recent guidelines and current expert recommendations Course objectives are reviewed annually with the faculty for currency and relevance and refined as necessary by the Course Director and selected physician advisors.

**Who Should Attend**The course is directed to specialty physicians.**Accreditation**The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.The Harvard Medical School designates this live activity for a maximum of 44.50 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity meets the criteria of the Massachusetts Board of Registration in Medicine for .75 credits of Risk Management Study. Please check your individual state licensing board requirements before claiming these credits.Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert *AMA PRA Category 1 Credit*™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting *AMA PRA Category 1 Credits*™ to ECMECs® can be found at: [**www.eaccme.eu**](http://www.eaccme.eu/).**ABMS/ACGME Competencies**This course is designed to enhance the following American Board of Medical Specialties and Accreditation Council of Graduate Medical Education competencies: patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, systems-based practice.**IOM Competencies**This course is designed to enhance the following Institute of Medicine competencies: provide patient-centered care, work in interdisciplinary teams, employ evidence-based practice.**Registration Information**Physician fee: **$1,600.00**Residents and Fellows in training **$1,600.00**Allied Health Professionals **$1,600.00**Early Registration Discount Rate **$1,350.00****Early Registration Deadline: May 31, 2017**Registration by credit card (VISA, MasterCard or American Express) can be made at[**http://cmeregistration.hms.harvard.edu/d/m5qm06/4W**](https://cmeregistration.hms.harvard.edu/d/m5qm06/4W). Registrations for Harvard Medical School CME programs are made via our secure online registration system. To register for this course, please visit the course website. At the end of the registration process, a Processing (non-refundable service fee) $5 will be added to your registration, and you will have the choice of paying by check or credit card (Visa, MasterCard, or American Express). If you are paying by check, the online registration system will provide you with instructions and a printable form for remitting your course fees by check. Postal, telephone, fax, and cash-payment registrations are not accepted. Upon receipt of your paid registration, an email confirmation from the HMS DCE office will be sent to you. Be sure to include an email address that you check frequently. Your email address is used for critical information, including registration confirmation, evaluation, and certificate. All fees shown in USD.**Inquiries**By phone **617-384-8600**, Mon – Fri, 9 am to 5 pm (ET) or by email at: **ceprograms@hms.harvard.edu**.**Disclosure Policy**Harvard Medical School (HMS) adheres to all ACCME Accreditation Criteria and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.**Refund Policy**Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior. “No shows” are subject to the full course fee and no refunds will be issued once the conference has started.**Accommodations/Travel**A limited number of rooms has been reserved at the Fairmont Copley Plaza Hotel, 138 St. James Avenue, Boston, MA 02116. Telephone: **617-267-5300** until September 2, 2017. Please specify that you are enrolled in this course to receive a conference rate. Hotel arrangements can also be made online at:[**https://resweb.passkey.com/go/dfci**](https://resweb.passkey.com/go/dfci). Please do not purchase nonrefundable airline ticket(s) until you have received an email from our office confirming your paid registration.**Disclaimer**CME activities sponsored by Harvard Medical School are offered solely for educational purposes and do not constitute any form of certification of competency. Practitioners should always consult additional sources of information and exercise their best professional judgment before making clinical decisions of any kind.**Schedule**

|  |
| --- |
| **SATURDAY, SEPTEMBER 23EVENING REGISTRATION 5:30 – 8:30 PM** |
| **SUNDAY, SEPTEMBER 24** |
| **Presiding: Dr. Mayer** |
| 7:00 am | Registration |  |
| 8:45 am | Welcome | Dr. Mayer |
| 9:00 am | Hemophilia-Related Syndromes | Dr. Neufeld |
| 10:00 am | Leukocyte Disorders | Dr. Parnes |
| **11:00 am** | **Break** |  |
| 11:15 am | Hemolytic Anemias | Dr. Connors |
| 12:15 pm | Bone Marrow Failure States | Dr. Brodsky |
| **1:15 pm** | **Adjourn/Lunch** |  |
| **Presiding: Dr. Mayer** |
| 2:15 pm | Thrombocytopenias | Dr. Kaushansky |
| 3:15 pm | Iron Deficiency and Iron Overload | Dr. Fleming |
| **4:00 pm** | **Break** |  |
| 4:15 pm | Hemoglobinopathies | Dr. Heeney |
| 5:15 pm | Advances in Cancer Drug Development | Dr. Shapiro |
| **6:15 pm** | **Adjourn** |  |
| **MONDAY, SEPTEMBER 25** |
| **Presiding: Dr. Mayer** |
| 8:00 am | Platelet Function and von Willebrand’s Disease | Dr. Handlin |
| 9:00 am | Hypercoagulable Syndromes and New Anticoagulant Therapies | Dr. Bauer |
| **10:15 am** | **Break** |  |
| 10:30 am | Stem Cell Biology and Hematopoietic Growth Factors | Dr. Kuter |
| 11:30 am | Panel Discussion (Drs. Bauer, Handlin, Kuter) |  |
| **12:00 pm** | **Lunch** |  |
| **Presiding: Dr. Kuter** |
| 1:00 pm | Molecular Genetics of Cancer | Dr. Wagle |
| 2:00 pm | Transfusion Medicine for the Clinician | Dr. Dzik |
| **3:00 pm** | **Break** |  |
| 3:15 pm | Infections in the Immunocompromised Host | Dr. Issa |
| 4:00 pm | Biology of Bone Marrow Transplantation | Dr. Soiffer |
| **5:00 pm** | **Adjourn** |  |
| **TUESDAY, SEPTEMBER 26** |
| **Presiding: Dr. Stone** |
| 8:00 am | Plasma Cell Neoplasms | Dr. Anderson |
| 9:00 am | Myelodysplasia | Dr. Steensma |
| 9:45 am | Acute Myeloid Leukemia | Dr. Stone |
| **10:30 am** | **Break** |  |
| 11:00 am | Chronic Myeloid Leukemia | Dr. DeAngelo |
| 11:45 am | Myeloproliferative Syndromes | Dr. Tefferi |
| 12:30 pm | Panel Discussion (Drs. Anderson, DeAngelo, Steensma, Stone, Tefferi) |  |
| **1:00 pm** | **Lunch** |  |
| **Presiding: Dr. Stone** |
| 2:00 pm | Low Grade Lymphoma | Dr. Abramson |
| 2:40 pm | High Grade Lymphoma | Dr. Freedman |
| **3:30 pm** | **Break** |  |
| 3:45 pm | Hodgkin’s Disease | Dr. LaCasce |
| 4:30 pm | CLL and Variants | Dr. Byrd |
| 5:15 pm | Panel Discussion (Drs. Abramson, Byrd, Freedman, LaCasce) |  |
| **5:45 pm** | **Adjourn** |  |
| 7:00–9:30 pm | 2017 ABIM Maintenance of Certification (MOC) Module | Drs. Burstein, DeAngelo, Mayer |
| **WEDNESDAY, SEPTEMBER 27** |
| **Presiding: Dr. Griffin** |
| 8:00 am | Neuroendocrine Tumors | Dr. Kulke |
| **Gastrointestinal Malignancies** |
| 8:30 am | Genetics and Screening | Dr. Syngal |
| 9:00 am | Esophageal and Gastric | Dr. Enzinger |
| **9:45 am** | **Break** |  |
| 10:00 am | Pancreas and Hepatobiliary | Dr. Ryan |
| 10:45 am | Colorectal and Anal | Dr. Mayer |
| 11:45 am | Panel Discussion (Drs. Enzinger, Kulke, Mayer, Ryan, Syngal) |  |
| **12:15 pm** | **Lunch** |  |
| **Presiding: Dr. Ryan** |
| 1:15 pm | Neuro-Oncology | Dr. Batchelor |
| 2:15 pm | Thymic Tumors and Mediastinal Germ Cell Tumors | Dr. Loehrer |
| 3:00 pm | Clinical Essentials of Palliative Care | Dr. Abrahm |
| **3:40 pm** | **Break** |  |
| 3:55 pm | Ovarian | Dr. Cannistra |
| 4:55 pm | Cervical, Endometrial, Trophoblastic | Dr. Matulonis |
| 5:45 pm | Panel Discussion (Drs. Cannistra, Matulonis) |  |
| **6:15 pm** | **Adjourn** |  |
| **THURSDAY, SEPTEMBER 28** |
| **Presiding: Dr. Canellos** |
| 8:00 am | Melanoma | Dr. Hodi |
| 9:00 am | Thyroid Cancer | Dr. Daniels |
| **10:00 am** | **Break** |  |
| 10:15 am | Head and Neck Cancer | Dr. Haddad |
| **Lung Cancer** |
| 11:05 am | First Line Non-Small Cell Lung Cancer | Dr. Jänne |
| 11:40 am | Second and Third Line Non-Small Cell Lung Cancer and Mesothelioma | Dr. Sequist |
| 12:15 pm | Targeted Therapy for Non-Small Cell and Small Cell Lung Cancer | Dr. Shaw |
| 12:45 pm | Panel Discussion (Drs. Haddad, Jänne, Sequist, Shaw) |  |
| **1:00 pm** | **Lunch** |  |
| **Presiding: Dr. Burstein** |
| 2:00 pm | Sarcoma and GIST | Dr. Demetri |
| **Genitourinary Cancer** |
| 3:00 pm | Testicular | Dr. Oh |
| **3:45 pm** | **Break** |  |
| 4:00 pm | Renal and Bladder | Dr. Chouieri |
| 4:45 pm | Prostate | Dr. Kantoff |
| 5:45 pm | Panel Discussion (Drs. Choueiri, Kantoff, Oh) |  |
| **6:15 pm** | **Adjourn** |  |
| 7:00–10:00 pm | **Dinner at the Harvard Club** |  |
| Topic: “The New Science of Therapeutics” Speaker: James E. Bradner, MD |
| **FRIDAY, SEPTEMBER 29** |
| **Presiding: Dr. WinerBreast Cancer** |
| 8:00 am | Survivorship Issues in Breast Cancer and Other Malignancies | Dr. Partridge |
| 9:00 am | Breast Cancer, Risk, Genetics and Prevention | Dr. Garber |
| 9:35 am | Pre-invasive Disease, Surgery, Radiation, Hormonal Therapy | Dr. Burstein |
| **10:15 am** | **Break** |  |
| 10:30 am | Adjuvant and Neoadjuvant Therapy | Dr. Winer |
| 11:10 am | Metastatic Disease | Dr. Krop |
| 11:50 am | Panel Discussion (Drs. Burstein, Garber, Krop, Partridge, Winer) |  |
| 12:15 pm | Concluding Remarks | Dr. Mayer |
|  | **Adjourn** |  |

**Faculty****Janet L. Abrahm, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Jeremy S. Abramson, MD**Assistant Professor of Medicine, Harvard Medical School, Massachusetts General Hospital**Kenneth C. Anderson, MD**Kraft Family Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Tracy T. Batchelor, MD, MPH**Giovanni Armenise Harvard Professor of Neurology, Harvard Medical School and Massachusetts General Hospital**Kenneth A. Bauer, MD**Professor of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center**James E. Bradner, MD**President, Novartis Institutes for BioMedical Research**Robert A. Brodsky, MD**Professor of Medicine, Johns Hopkins School of Medicine and Chief of Hematology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland**Harold J. Burstein, MD, PhD**Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**John C. Byrd, MD**Professor Medicine and Medicinal Chemistry, Ohio State University**George P. Canellos, MD**William Rosenberg Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Stephen A. Cannistra, MD**Professor of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center**Toni K. Choueiri, MD**Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Jean M. Connors, MD**Assistant Professor Medicine, Harvard Medical School and Brigham and Women’s Hospital**Gilbert H. Daniels, MD**Professor of Medicine, Harvard Medical School and Massachusetts General Hospital**Daniel J. DeAngelo, MD, PhD**Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**George D. Demetri, MD**Professor of Medicine, Harvard Medical School and Dana Farber Cancer Institute**Walter H. Dzik, MD**Associate Professor of Pathology, Harvard Medical School and Massachusetts General Hospital**Peter C. Enzinger, MD**Assistant Professor of Medicine, Harvard Medical School and Dana Farber Cancer Institute**Mark D. Fleming, MD, PhD**S. Burt Wolbach Professor of Pathology, Harvard Medical School and Children’s Hospital Boston**Arnold S. Freedman, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Judy E. Garber, MD, MPH**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**James D. Griffin, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Robert I. Haddad, MD**Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Robert I. Handin, MD**Professor of Medicine, Harvard Medical School and Brigham and Women’s Hospital**Matthew M. Heeney, MD**Assistant Professor of Pediatrics, Harvard Medical School and Boston Children’s Hospital**F. Stephen Hodi, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Nicolas C. Issa, MD**Assistant Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital**Pasi A. Jänne, MD, PhD**Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute**Bruce E. Johnson, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Philip W. Kantoff, MD**Chairman of Medicine and George J. Bosl Chair in Medicine, Memorial Sloan Kettering Cancer Center**Kenneth Kaushansky, MD**Senior Vice President of the Health Sciences and Dean of the School of Medicine, Stony Brook University, Stony Brook, New York**Ian E. Krop, MD, PhD**Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Matthew H. Kulke, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**David J. Kuter, MD, DPhil**Professor of Medicine, Harvard Medical School and Massachusetts General Hospital**Ann S. LaCasce, MD**Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Patrick J. Loehrer, Sr, MD**Director, Indiana University Melvin and Bren Simon Cancer Center, H.H. Gregg Professor of Oncology and Associate Dean for Cancer Research, Indiana University School of Medicine**Ursula A. Matulonis, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Robert J. Mayer, MD**Stephen B. Kay Family Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Ellis J. Neufeld, MD, PhD**Clinical Director, Physician-in-Chief and Executive Vice President, St. Jude Children’s Research Hospital, Memphis, Tennessee**William K. Oh, MD**Professor of Medicine and Urology, Mount Sinai School of Medicine and Chief, Division of Hematology-Oncology, Mount Sinai Comprehensive Cancer Center, New York, New York**Aric D. Parnes, B.Ch.**Instructor in Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Ann H. Partridge, MD, MPH**Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**David P. Ryan, MD**Professor of Medicine, Harvard Medical School and Massachusetts General Hospital**Lecia V. Sequist, MD**Landry Family Associate Professor of Medicine in the Field of Medical Oncology, Harvard Medical School, Massachusetts General Hospital**Geoffrey I. Shapiro, MD, PhD**Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Alice T. Shaw, MD, PhD**Associate Professor of Medicine, Harvard Medical School and Massachusetts General Hospital**Robert J. Soiffer, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**David P. Steensma, MD**Associate Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Richard M. Stone, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Sapna Syngal, MD, MPH**Professor of Medicine, Harvard Medical School and Brigham and Women’s Hospital**Ayalew Tefferi, MD**Professor of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota**Nikhil Wagle, MD**Assistant Professor of Medicine, Harvard Medical School and Dana-Farber Cancer Institute**Eric P. Winer, MD**Professor of Medicine, Harvard Medical School and Dana-Farber Cancer InstituteCopyright © 2017, Harvard Medical SchoolLast update 4.11.2017 |